How do I buy Atara Biotherapeutics, Inc. Common Stock (ATRA) stock?

Buying Atara Biotherapeutics, Inc. Common Stock (ATRA) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "ATRA", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy ATRA by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if ATRA is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock

Q: What is the minimum investment for ATRA on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Atara Biotherapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · ATRA

Trade ATRA

Key stats

Market cap: $83.85M
Price / Earnings ratio: -4.9x
EPS (TTM): -$1.28
Volume: Loading
52-week high: $19.15
52-week low: $3.92

Source: third-party data provider, as of November 13, 2026

Compare with ATRA

Technical indicators

RSI 14: 44.67
MACD 12/26/9: -0.28
EMA 9 of MACD: -0.25
MACD histogram: -0.03
SMA 50: $9.01; Price below SMA 50
EMA 50: $8.79; Price below EMA 50
SMA 200: $7.81; Price above SMA 200
EMA 200: $8.91; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

No analyst data available

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

155M102M51M0

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

562M371M185M0

Revenue to Profit

2025

$120.8M

Revenue

$0.0

Cost of revenue

$99.6M

Gross profit

$0.0

Operating expenses

$32.7M

Net income

Earnings

No data available

Source: third-party data provider

About Atara Biotherapeutics, Inc. Common Stock

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

SectorHealthcare

IndustryBiotechnology

Employees10

CEODr. Anhco Nguyen Ph.D.

IPO DateOct 16, 2014

HeadquartersThousand Oaks, CA

Key Executives

Name	Title	Year Born
Dr. Anhco Nguyen Ph.D.	President, CEO & Director	1973
Mr. Kevin G. Sarney CPA	Interim Chief Financial Officer	1965
Mr. Jim Sesic	Senior Vice President of Regulatory Affairs	—

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026					+9.4	+11.7	-26.3	+4.1	-5.8	-5.3	-2.9

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Atara Biotherapeutics, Inc. Common Stock (ATRA) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "ATRA", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy ATRA by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Atara Biotherapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Atara Biotherapeutics, Inc. Common Stock (ATRA) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track ATRA's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock

Key stats

Compare with ATRA

Recent news

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Changes to Its Board of Directors

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Changes to Its Board of Directors

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

ATRA Stock Sees Biggest Single-Day Gain In Over 2 Years, Breaches Key Technical Milestone – New FDA Update Has Bulls Circling Back

ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection

ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection

About Atara Biotherapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade